يعرض 1 - 20 نتائج من 323 نتيجة بحث عن '"Casbard, A"', وقت الاستعلام: 0.56s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal

    وصف الملف: application/pdf

    Relation: https://orca.cardiff.ac.uk/id/eprint/173225/1/mapping-the-pathway-and-support-offered-to-children-with-an-intellectual-disability-referred-to-specialist-mental-health-services-in-the-uk.pdf; Totsika, Vaso, Yang, Zhixing, Turner, Lauren, Kohn, Charmaine, Hassiotis, Angela, Kennedy, Eilis, Absoud, Michael, McNamara, Rachel https://orca.cardiff.ac.uk/view/cardiffauthors/A0682212.html orcid:0000-0002-7280-1611 orcid:0000-0002-7280-1611, Randell, Elizabeth https://orca.cardiff.ac.uk/view/cardiffauthors/A115878J.html orcid:0000-0002-1606-3175 orcid:0000-0002-1606-3175, Levitt, Sophie, Grant, Gemma, Casbard, Angela https://orca.cardiff.ac.uk/view/cardiffauthors/A111881N.html orcid:0000-0001-6241-3052 orcid:0000-0001-6241-3052, Jacobs, Lauris, Di Santo, Cristina, Buckley, Claire, Hignett, Emma and Liew, Ashley 2024. Mapping the pathway and support offered to children with an intellectual disability referred to specialist mental health services in the UK. BJPsych Bulletin 10.1192/bjb.2024.63 https://doi.org/10.1192/bjb.2024.63 file https://orca.cardiff.ac.uk/id/eprint/173225/1/mapping-the-pathway-and-support-offered-to-children-with-an-intellectual-disability-referred-to-specialist-mental-health-services-in-the-uk.pdf

  4. 4
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
  9. 9
    Conference

    Relation: Ajakaiye, Anu, Brogden, Elena https://orca.cardiff.ac.uk/view/cardiffauthors/A27597095.html, Murphy, Jamie, Peters, Christopher, Frost, Jonathan, Adams, Richard https://orca.cardiff.ac.uk/view/cardiffauthors/A104870D.html orcid:0000-0003-3915-7243 orcid:0000-0003-3915-7243, Hudson, Emma, Perry, Kitrick, Casbard, Angela https://orca.cardiff.ac.uk/view/cardiffauthors/A111881N.html orcid:0000-0001-6241-3052 orcid:0000-0001-6241-3052, Hamilton, Rebecca https://orca.cardiff.ac.uk/view/cardiffauthors/A2533687U.html, Nixon, Lisette https://orca.cardiff.ac.uk/view/cardiffauthors/A047019C.html orcid:0000-0002-1270-6970 orcid:0000-0002-1270-6970, Arndell, Karen, Gwynne, Sarah, Torkington, Jared https://orca.cardiff.ac.uk/view/cardiffauthors/A215102M.html and Jones, Sadie https://orca.cardiff.ac.uk/view/cardiffauthors/A0433390.html 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting, Dublin, Ireland, 16-18 October 2024. International Journal of Gynecological Cancer. , vol.34 BMJ Publishing Group, A350-A351. 10.1136/ijgc-2024-IGCS.611 https://doi.org/10.1136/ijgc-2024-IGCS.611

  10. 10
  11. 11
    Academic Journal

    وصف الملف: text

    Relation: https://eprints.soton.ac.uk/457629/1/2022_active_symptom_control_with_or_without_oral_vinorelbine_VIM.pdf; Porter, Catharine, Lester, Jason, Danson, Sarah, Taylor, Paul, Sheaff, Michael, Rudd, Robin M., Gaba, Aarti, Busacca, Sara, Nixon, Lisette, Gardner, Georgina, Darlison, Liz, Poile, Charlotte, Richards, Cathy, Jordan, Peter-Wells, Griffiths, Gareth and Casbard, Angela (2022) Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial. EClinicalMedicine, 48, [101432]. (doi:10.1016/j.eclinm.2022.101432 ).

  12. 12
    Academic Journal

    المصدر: Howell , S J , Casbard , A , Carucci , M , Ingarfield , K , Butler , R , Morgan , S , Meissner , M , Bale , C , Bezecny , P , Moon , S , Twelves , C , Venkitaraman , R , Waters , S , de Bruin , E C , Schiavon , G , Foxley , A & Jones , R H 2022 , ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated ....

  13. 13
    Academic Journal

    وصف الملف: text

    Relation: https://eprints.whiterose.ac.uk/187975/6/PIIS1470204522002844.pdf; Howell, SJ, Casbard, A, Carucci, M et al. (14 more authors) (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology, 23 (7). pp. 851-864. ISSN 1470-2045

  14. 14
    Academic Journal
  15. 15
    Conference
  16. 16
    Academic Journal

    المصدر: Jones , R , Casbard , A , Carucci , M , Cox , C , Butler , R , Alchami , F , Madden , T-A , Bale , C , Bezecny , P , Joffe , J , Moon , S , Twelves , C , Venkitaraman , R , Waters , S , Foxley , A & Howell , S 2020 , ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ' , The Lancet Oncology ....

  17. 17
  18. 18
    Academic Journal

    وصف الملف: text

    Relation: http://eprints.gla.ac.uk/215667/1/215667.pdf; Jones, R. et al. (2020) A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin. BJU International , 126(2), pp. 292-299. (doi:10.1111/bju.15096 ) (PMID:32336008)

  19. 19
  20. 20

    المصدر: Howell, S J, Casbard, A, Carucci, M, Ingarfield, K, Butler, R, Morgan, S, Meissner, M, Bale, C, Bezecny, P, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, de Bruin, E C, Schiavon, G, Foxley, A & Jones, R H 2022, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial ', The Lancet. Oncology, vol. 23, no. 7, pp. 851-864 . https://doi.org/10.1016/S1470-2045(22)00284-4